Your browser doesn't support javascript.
loading
Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
Balloy, G; Pelletier, J; Suchet, L; Lebrun, C; Cohen, M; Vermersch, P; Zephir, H; Duhin, E; Gout, O; Deschamps, R; Le Page, E; Edan, G; Labauge, P; Carra-Dallieres, C; Rumbach, L; Berger, E; Lejeune, P; Devos, P; N'Kendjuo, J-B; Coustans, M; Auffray-Calvier, E; Daumas-Duport, B; Michel, L; Lefrere, F; Laplaud, D A; Brosset, C; Derkinderen, P; de Seze, J; Wiertlewski, S.
Afiliação
  • Balloy G; Neurology Department, University of Nantes Hospital, Nantes, France. gaelle.balloy@chu-nantes.fr.
  • Pelletier J; Service de Neurologie, Hopital Laennec, Boulevard Jacques Monod, 44800, Saint Herblain, France. gaelle.balloy@chu-nantes.fr.
  • Suchet L; Neurosciences Unit, Neurology Department, Timone Hospital, Aix Marseille University, APHM, Marseille, France.
  • Lebrun C; Neurosciences Unit, Neurology Department, Timone Hospital, Aix Marseille University, APHM, Marseille, France.
  • Cohen M; University of Nice Hospital, Nice, France.
  • Vermersch P; University of Nice Hospital, Nice, France.
  • Zephir H; University of Lille Hospital, Lille, France.
  • Duhin E; University of Lille Hospital, Lille, France.
  • Gout O; University of Lille Hospital, Lille, France.
  • Deschamps R; Rothschild Foundation, Paris, France.
  • Le Page E; Rothschild Foundation, Paris, France.
  • Edan G; University of Rennes Hospital, Rennes, France.
  • Labauge P; University of Rennes Hospital, Rennes, France.
  • Carra-Dallieres C; University of Montpellier Hospital, Montpellier, France.
  • Rumbach L; University of Montpellier Hospital, Montpellier, France.
  • Berger E; University Besançon Hospital, Besançon, France.
  • Lejeune P; University Besançon Hospital, Besançon, France.
  • Devos P; La Roche sur Yon Hospital, La Roche-sur-Yon, France.
  • N'Kendjuo JB; Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.
  • Coustans M; Dunkerque Hospital, Dunkerque, France.
  • Auffray-Calvier E; Cornouaille Hospital, Quimper, France.
  • Daumas-Duport B; Radiology Department, University of Nantes Hospital, Nantes, France.
  • Michel L; Radiology Department, University of Nantes Hospital, Nantes, France.
  • Lefrere F; Neurology Department, University of Nantes Hospital, Nantes, France.
  • Laplaud DA; Neurology Department, University of Nantes Hospital, Nantes, France.
  • Brosset C; Neurology Department, University of Nantes Hospital, Nantes, France.
  • Derkinderen P; Military Hospital, Marseille, France.
  • de Seze J; Neurology Department, University of Nantes Hospital, Nantes, France.
  • Wiertlewski S; University of Strasbourg Hospital, Strasbourg, France.
J Neurol ; 265(10): 2251-2259, 2018 Oct.
Article em En | MEDLINE | ID: mdl-30054790
BACKGROUND: Tumefactive demyelinating lesions of the central nervous system can be the initial presentation in various pathological entities [multiple sclerosis (the most common), Balo's concentric sclerosis, Schilder's disease and acute disseminated encephalomyelitis] with overlapping clinical presentation. The aim of our study was to better characterize these patients. METHODS: Eighty-seven patients (62 women and 25 men) from different MS centers in France were studied retrospectively. Inclusion criteria were (1) a first clinical event (2) MRI showing one or more large demyelinating lesions (20 mm or more in diameter) with mass-like features. Patients with a previous demyelinating event (i.e. confirmed multiple sclerosis) were excluded. RESULTS: Mean age at onset was 26 years. The most common initial symptoms (67% of the patients) were hemiparesis or hemiplegia. Aphasia, headache and cognitive disturbances (i.e. atypical symptoms for demyelinating diseases) were observed in 15, 18 and 15% of patients, respectively. The mean largest diameter of the tumefactive lesions was 26.9 mm, with gadolinium enhancement in 66 patients (81%). Twenty-one patients (24%) had a single tumefactive lesion. During follow-up (median time 5.7 years) 4 patients died, 70 patients improved or remained stable and 12 worsened. 86% of patients received initial corticosteroid treatment, and 73% received disease-modifying therapy subsequently. EDSS at the end of the follow-up was 2.4 ± 2.6 (mean ± SD). CONCLUSION: This study provides further evidence that the clinical course of MS presenting with large focal tumor-like lesions does not differ from that of classical relapsing-remitting MS, once the noisy first relapsing occurred.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: J Neurol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: J Neurol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França